FDA push­es back PDU­FA date for Dai­ichi's AML drug quizar­tinib over REMS up­dates

Dai­ichi Sankyo said the FDA needs more time to re­view the NDA for its FLT3 drug quizar­tinib, ex­tend­ing the PDU­FA date by three months un­til …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.